Hoya Vision Care Expands MiYOSMART Power Range for High Myopia Treatment in Children

Hoya Vision Care announced the launch of an extended power range for its MiYOSMART spectacle lenses, offering a new solution for children suffering from high myopia. Designed specifically to address the needs of high myopic patients, the new lenses feature a broader range of prescriptions, slimmer edge thickness, and compatibility with a wider variety of frames, aiming to provide greater comfort and adaptability for young patients, according to Hoya. 

By 2050, myopia is projected to affect 938 million people worldwide—nearly 10% of the global population.[1] This rise is attributed to lifestyle changes, such as increased screen time and reduced outdoor activity.[2] Beyond its impact on vision, high myopia elevates the risk of potentially irreversible complications, including myopic macular degeneration and blindness.

“Slowing down the progression of myopia by just one diopter can reduce the risk of myopic maculopathy by 40%," Natalia Vlasak, MD, Global Head of Medical and Scientific Affairs at Hoya Vision Care, said in a company news release. "With the extension of MiYOSMART’s power range to treat high myopia, we are equipping children with a critical tool to safeguard their vision health for the future.”

The new MiYOSMART power range accommodates prescriptions up to -13.00 D and cylindrical power up to 4.00 D, addressing both high myopia and astigmatism. The lenses’ larger diameters allow for their integration into larger frames, making them suitable for older children and teenagers with wider pupillary distances or aesthetic preferences. Optimized lens edge thickness further enhances comfort and wearability.

Since its debut in 2018, over 10 million MiYOSMART spectacle lenses have been sold across more than 40 countries. MiYOSMART lenses are not approved or available for sale in all countries, including the United States.

References

1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-1042. doi: 10.1016/j.ophtha.2016.01.006.
2. Morgan IG, Wu PC, Ostrin LA, et al. IMI Risk Factors for Myopia. Invest Ophthalmol Vis Sci. 2021;62(5):3. doi: https://doi.org/10.1167/iovs.62.5.3.